PLEASANTON, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Thoratec Corporation , a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it will webcast its investor event to discuss data from the HeartMate II Destination Therapy clinical trial that will be presented during the late-breaking clinical trial session at the American Heart Association(AHA) Scientific Sessions 2009.
The event will include a review of the trial data by Dr. Joseph Rogers of Duke University, who is presenting the data at AHA as a late-breaking clinical trial, and comments from Gary F. Burbach, president and chief executive officer of Thoratec.
Thoratec Corporation
